Filing Flows › Janux Therapeutics (JANX) › R&D spending
Janux Therapeutics (JANX) R&D spending by quarter
Janux Therapeutics' R&D spending was $30.6M in Q3 2026 (third quarter 2026), -1% from Q2 2026. Over the last 4 quarters it ranged from $26.8M (Q1 2026) to $34.6M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $30.6M | -1% | -12% |
| Q2 2026 | $31.0M | +16% | — |
| Q1 2026 | $26.8M | -23% | — |
| Q3 2025 | $34.6M | — | — |
Q3 2026 at a glance
Janux Therapeutics, Q3 2026: revenue $9.3M (-7% year over year), operating margin -336.5%, net loss $21.6M, operating cash flow −$25.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Janux Therapeutics' R&D spending?
Janux Therapeutics' R&D spending was $30.6M in Q3 2026 (third quarter 2026), -1% from Q2 2026.
How has Janux Therapeutics' R&D spending changed?
Over the last 4 quarters it ranged from $26.8M (Q1 2026) to $34.6M (Q3 2025).